Published in Clinical Oncology Week, July 20th, 2009
TLC is developing and commercializing a portfolio of "super-generics" with advantageous delivery or formulation characteristics. Some of these products include TLC's lead product, ProFlow (used to treat peripheral arterial disease and diabetic neuropathy), which is currently undergoing product development and registration in Asian markets....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.